Survodutide
Also known as: BI 456906, GCGR/GLP-1R dual agonist, glucagon receptor/GLP-1 receptor dual agonist
Dual glucagon receptor (GCGR) / glucagon-like peptide-1 receptor (GLP-1R) agonist; investigational peptide therapeutic
What it is
Survodutide is an investigational weight-loss drug in Phase 3 clinical trials for obesity and metabolic liver disease. It activates two hormone pathways to cut appetite and increase fat burning. Not FDA-approved; Phase 3 trials ongoing; showing strong results in liver fibrosis and weight reduction.
The scientific side
Survodutide (BI 456906) is a 29-amino acid peptide derived from glucagon that acts as a dual agonist at both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). It contains a C18 diacid moiety that mediates binding to albumin, prolonging its half-life to enable once-weekly subcutaneous dosing. GLP-1R agonism suppresses appetite and stimulates insulin secretion, while GCGR agonism aims to enhance body-weight-lowering effects by increasing energy expenditure and stimulating hepatic lipolysis and mitochondrial fat oxidation. Preclinically, survodutide demonstrated body weight-lowering efficacy through decreased energy intake and increased energy expenditure. In the central nervous system, survodutide accesses circumventricular organs (CVOs) and adjacent hypothalamic and hindbrain nuclei without uniformly crossing the blood-brain barrier; c-Fos labeling showed activation of multiple nuclei associated with control of food intake, with the intake-suppressive effects being GLP-1R-dependent. The natural gut hormone oxyntomodulin is a weak dual GCGR/GLP-1R agonist; survodutide was developed to mimic and potentiate this mechanism. Regarding liver effects, mediation analysis in a MASH phase 2 trial indicated that endpoints related to improvements in inflammation and fibrosis were predominantly weight-reduction-independent, suggesting a potential direct role of glucagon receptor agonism in the liver.
Class: Dual glucagon receptor (GCGR) / glucagon-like peptide-1 receptor (GLP-1R) agonist; investigational peptide therapeutic
Administration & storage
- Administration
- Subcutaneous injectiononce weekly (PMID: 42253238)Subcutaneous injectiononce weekly (PMID: 38330987)Subcutaneous injectiononce weekly (PMID: 38847460)Subcutaneous injectiononce weekly (PMID: 42252333)Subcutaneous injectiononce weekly or twice weekly (PMID: 38095657)Subcutaneous injectionsingle dose and multiple doses (PMID: 38857788)
- Storage
- Storage conditions for survodutide are not described in the reviewed abstracts.
- Cautions
- Gastrointestinal adverse events (nausea, vomiting, diarrhea) are the most common class effects, occurring in approximately 75-90% of survodutide-treated participants in clinical trials, typically during dose escalation, and are generally mild to moderate (PMID: 42253238, PMID: 38847460, PMID: 38330987).,Survodutide is an investigational drug and is not approved by any regulatory authority reviewed in the available literature; it should only be used within the context of authorized clinical trials.,In a phase 1 trial in people with cirrhosis, drug-related adverse events occurred in up to 87.5% of cirrhotic participants during multi-dose escalation to 6.0 mg; careful monitoring is warranted in hepatically impaired populations.,Preliminary data suggest survodutide may increase heart rate to a similar extent as GLP-1 receptor monoagonists; cardiovascular safety is being evaluated in the ongoing SYNCHRONIZE-CVOT trial (PMID: 42535526, PMID: 39453356).,Higher doses of survodutide (>2.4 mg/week) were associated with a higher risk of treatment discontinuation due to gastrointestinal adverse events; dose escalation rate may mitigate gastrointestinal adverse events (PMID: 40922121, PMID: 38095657).,Sterile technique is essential for subcutaneous self-injection to prevent injection-site infection (universal caution, no specific PMID required).
Legal & regulatory status
Not approved; investigational drug under phase 3 clinical development (PMID: 42253238, PMID: 42252333). Not stated as approved in reviewed literature — requires manual verification.
Not stated in reviewed literature — requires manual verification.
Not stated in reviewed literature — requires manual verification.
What it's studied for
- Obesity (without type 2 diabetes) Human RCT
- In 725 adults with obesity without diabetes (BMI ≥30 or ≥27 with ≥1 complication), once-weekly subcutaneous survodutide (up to 3.6 mg or 6.0 mg) for 76 weeks produced mean body weight changes of -12.2% (3.6 mg) and -13.0% (6.0 mg) vs. -5.4% with placebo (P<0.001 for both). 72.6% (3.6 mg) and 71.9% (6.0 mg) achieved ≥5% PMID 42253238 le Roux CW et al. N Engl J Med. 2026. SYNCHRONIZE-1 phase 3 RCT.
- In 387 adults (BMI ≥27, without diabetes) randomized to survodutide (0.6, 2.4, 3.6, or 4.8 mg once weekly) or placebo for 46 weeks, mean bodyweight changes were -6.2% (0.6 mg), -12.5% (2.4 mg), -13.2% (3.6 mg), and -14.9% (4.8 mg) vs. -2.8% with placebo. All doses were tolerated and dose-dependently reduced bodyweight. PMID 38330987 le Roux CW et al. Lancet Diabetes Endocrinol. 2024. Phase 2 RCT.
- Subgroup analysis by sex and BMI showed females had greater reductions in bodyweight and waist circumference than males; participants with lower baseline BMI had greater proportional bodyweight reductions. Nausea was the most frequently reported gastrointestinal AE in all subgroups. PMID 39821928 le Roux CW et al. Diabetes Obes Metab. 2025. Phase 2 subgroup analysis.
- Obesity with type 2 diabetes Human RCT
- In 413 participants with type 2 diabetes on metformin (HbA1c 7.0-10.0%, BMI 25-50 kg/m²), survodutide (up to 0.3–2.7 mg once weekly or 1.2–1.8 mg twice weekly) significantly reduced HbA1c dose-dependently and bodyweight (up to -8.7% at highest dose) after 16 weeks vs. placebo. Survodutide ≥1.8 mg once weekly produced g PMID 38095657 Blüher M et al. Diabetologia. 2024. Phase 2 RCT.
- SYNCHRONIZE-2 enrolled 752 participants with obesity and T2D (mean BMI 36.5 kg/m², HbA1c 7.4%) randomized to once-weekly subcutaneous survodutide (up-titrated to 3.6 or 6.0 mg) or placebo for 76 weeks. Primary endpoints are percentage body weight change and ≥5% body weight reduction at week 76. Results pending. PMID 41216778 Wharton S et al. Diabetes Obes Metab. 2026. SYNCHRONIZE-2 phase 3 baseline characteristics.
- Metabolic dysfunction-associated steatohepatitis (MASH) / MASLD Human RCT
- In 293 adults with biopsy-confirmed MASH and fibrosis F1-F3, once-weekly subcutaneous survodutide (2.4, 4.8, or 6.0 mg) for 48 weeks led to MASH improvement without fibrosis worsening in 47% (2.4 mg), 62% (4.8 mg), and 43% (6.0 mg) vs. 14% placebo (P<0.001). ≥30% liver fat reduction occurred in 63%, 67%, 57% vs. 14% pl PMID 38847460 Sanyal AJ et al. N Engl J Med. 2024. Phase 2 RCT.
- In 216 adults with obesity and at-risk MASLD (MASH with inflammation/fibrosis by NITs or biopsy-confirmed MASH), survodutide 6.0 mg once weekly subcutaneously for 48 weeks achieved ≥30% liver fat reduction in 84.2% vs. 24.3% placebo (efficacy estimand, P<0.0001) and mean body weight change of -12.2% vs. -1.0% placebo ( PMID 42252333 Kaplan LM et al. Nature Medicine. 2026. SYNCHRONIZE-MASLD phase 3 RCT.
- Post hoc mediation analysis of the phase 2 MASH trial (F2-F3 participants) showed that for MASH resolution without worsening fibrosis, 66.7% of the total treatment effect was mediated by weight reduction (indirect), whereas for fibrosis improvement without worsening MASH, only 36.3% was mediated by weight reduction, su PMID 42545725 Noureddin M et al. Hepatology. 2026. Mediation analysis of MASH phase 2 trial.
- In an open-label phase 1 trial in people with cirrhosis (Child-Pugh A, B, or C), a single subcutaneous dose of survodutide 0.3 mg showed similar pharmacokinetics (AUC and Cmax) in cirrhotic vs. healthy individuals; no pharmacokinetic-related dose adjustment is required. In multiple-dose cohorts escalated to 6.0 mg over PMID 38857788 Lawitz EJ et al. J Hepatol. 2024. Phase 1 cirrhosis trial.
- Glycemic control and beta-cell function (type 2 diabetes and overweight/obesity) Human RCT
- In adults with type 2 diabetes (n=413), survodutide significantly increased HOMA-β, decreased HOMA-IR, glucagon, and fasting plasma glucose vs. placebo. In adults with overweight/obesity and normoglycemia (n=387), survodutide significantly decreased HOMA-IR, glucagon, C-peptide, fasting insulin, and fasting plasma gluc PMID 42331726 Ekinci EI et al. Diabetes Obes Metab. 2026. Post hoc phase 2 analysis.
- Cardiovascular outcomes (safety/efficacy in obesity with elevated CV risk) Human RCT
- SYNCHRONIZE-CVOT is an ongoing phase 3, randomized, double-blind, event-driven cardiovascular safety study of survodutide (once weekly subcutaneous) vs. placebo in adults with BMI ≥27 kg/m² and established CV disease or chronic kidney disease, targeting 4,935 participants. Primary endpoint: time to first 5-point MACE. PMID 39453356 Kosiborod MN et al. JACC Heart Fail. 2024. SYNCHRONIZE-CVOT protocol.
- Obesity in Japanese adults (with or without type 2 diabetes) Human RCT
- SYNCHRONIZE-JP enrolled 274 Japanese adults with obesity disease (mean age 53.1 years, mean BMI 33.2 kg/m², 47.8% female, 24.1% with T2D) randomized 1:1:1 to once-weekly survodutide 3.6 mg, 6.0 mg, or placebo for 76 weeks. Most frequent complications: dyslipidemia (81.4%), hypertension (72.6%). Results pending. PMID 42219222 Yokote K et al. Diabetes Obes Metab. 2026. SYNCHRONIZE-JP phase 3 trial design and baseline characteristics.
- Preclinical weight loss and metabolic outcomes Animal studies only
- In diet-induced obese (DIO) mice, survodutide (30 nmol/kg once daily) achieved body weight-lowering efficacy from baseline of 25%. In db/db mice, survodutide (10 and 20 nmol/kg once daily) significantly lowered glycated hemoglobin (0.4%-0.6%). Survodutide was selected as the clinical candidate based on balanced dual GC PMID 38560764 Thomas L et al. Diabetes Obes Metab. 2024. Preclinical pharmacological profiling.
- Using fluorophore-labeled survodutide, survodutide accessed circumventricular organs (CVOs) and adjacent hypothalamic and hindbrain nuclei in mice without uniformly crossing the blood-brain barrier. c-Fos labeling showed activation of multiple food intake-regulating nuclei. GCGR expression was barely detectable in area PMID 41638399 Zimmermann T et al. Mol Metab. 2026. Brain mechanism study in mice.
- In diet-induced obese mice, combination of the NPY2R agonist BI 1820237 with survodutide led to 22% bodyweight reduction, significantly greater (P<0.01) than 17% with survodutide alone. Regression-based interaction analysis demonstrated BI 1820237 increased the efficacy of survodutide by 265% at an ED50 of 11.7 nmol/kg PMID 40619099 Augustin R et al. Mol Metab. 2025. NPY2R/GCGR/GLP-1R combination study in mice.
Safety signals
- Gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) are the most frequently reported adverse events, occurring in 80.9% (3.6 mg) and 89.7% (6.0 mg) of survodutide-treated participants vs. 47.9% placebo in phase 3 SYNCHRONIZE-1; events were typically mild to moderate and occurred primarily during dose escalation. PMID 42253238
- In the phase 2 MASH trial, nausea occurred in 66% vs. 23% placebo, diarrhea in 49% vs. 23% placebo, and vomiting in 41% vs. 4% placebo; serious adverse events in 8% survodutide vs. 7% placebo. PMID 38847460
- Higher risk of treatment discontinuation due to adverse events with survodutide compared with placebo, with gastrointestinal AEs being the most common cause; no significant increase in the incidence of serious AEs was observed across trials included in meta-analysis. PMID 40922121
- In the phase 2 obesity trial, adverse events occurred in 91% of survodutide recipients (primarily gastrointestinal, 75%) vs. 75% placebo; dose-related gastrointestinal AEs could be mitigated with slower dose escalation. PMID 38330987
- In cirrhotic patients (phase 1), drug-related adverse events occurred in up to 87.5% of those with cirrhosis during multi-dose escalation to 6.0 mg; pharmacokinetics (AUC, Cmax) were similar in cirrhotic individuals and healthy controls after single-dose, suggesting no pharmacokinetic-related dose adjustment required. PMID 38857788
- Clinical studies of survodutide found increased heart rate to a similar extent as GLP-1 receptor monoagonists, and reduced blood pressure; cardiovascular safety is being investigated in the ongoing SYNCHRONIZE-CVOT cardiovascular outcomes trial. PMID 42535526
- No deaths were reported in the phase 3 SYNCHRONIZE-1 trial across 725 participants over 76 weeks. PMID 42253238
Contraindications
- Type 2 diabetes was an exclusion criterion in the SYNCHRONIZE-1 phase 3 obesity trial and in the phase 2 obesity dose-finding trial; separate trials (SYNCHRONIZE-2) were designed for participants with T2D. PMID 42253238
- Cirrhosis with decompensated liver disease (Child-Pugh B or C) is not a blanket contraindication based on pharmacokinetic data, but people with decompensated cirrhosis are typically excluded from standard clinical trials; phase 1 data suggest monitoring is required in this population. PMID 38857788
- Participants with prior or ongoing use of protocol-prohibited obesity medications were excluded or accounted for as protocol deviations in efficacy analyses in phase 3 trials. PMID 42253238
Protocol
No community protocol on record. In clinical studies, Survodutide was dosed at 3.6 mg or 6.0 mg once weekly, up-titrated subcutaneous injection (PMID 42253238).
All studies (19)
- PMID 38095657 Human RCT
Obesity with type 2 diabetes - PMID 38330987 Human RCT
Obesity (without type 2 diabetes) - PMID 38847460 Human RCT
Metabolic dysfunction-associated steatohepatitis (MASH) / MASLD - PMID 38857788 Human RCT
Metabolic dysfunction-associated steatohepatitis (MASH) / MASLD - PMID 39453356 Human RCT
Cardiovascular outcomes (safety/efficacy in obesity with elevated CV risk) - PMID 39821928 Human RCT
Obesity (without type 2 diabetes) - PMID 41216778 Human RCT
Obesity with type 2 diabetes - PMID 42219222 Human RCT
Obesity in Japanese adults (with or without type 2 diabetes) - PMID 42252333 Human RCT
Metabolic dysfunction-associated steatohepatitis (MASH) / MASLD - PMID 42253238 Human RCT
Obesity (without type 2 diabetes) - PMID 42331726 Human RCT
Glycemic control and beta-cell function (type 2 diabetes and overweight/obesity) - PMID 42545725 Human RCT
Metabolic dysfunction-associated steatohepatitis (MASH) / MASLD - PMID 26
Up-titrated to 3.6 or 6.0 mg once weekly; dose flexibility permitted subcutaneous injection (human) - PMID 37330144
- PMID 38560764 Animal studies only
Preclinical weight loss and metabolic outcomes - PMID 40619099 Animal studies only
Preclinical weight loss and metabolic outcomes - PMID 40922121
Higher risk of treatment discontinuation due to adverse events with survodutide compared with placebo, with gastrointestinal AEs being the most common cause; no - PMID 41638399 Animal studies only
Preclinical weight loss and metabolic outcomes - PMID 42535526
Clinical studies of survodutide found increased heart rate to a similar extent as GLP-1 receptor monoagonists, and reduced blood pressure; cardiovascular safety